Atrial fibrillation in chronic kidney disease - treatment standard

The prevalence of atrial fibrillation (AF) is high among patients with chronic kidney disease (CKD). While patients with CKD Stages G1 - G3b may be treated similarly to patients without CKD, little evidence guides therapeutic strategies for CKD G4 - G5 patients. Dosing of most drugs used for rate and rhythm control requires adjustment to kidney function. Recurrence rates after cardioversion and ablation for rhythm control are higher in patients with advanced CKD than those without it. Regarding the prevention of stroke and systemic embolism, the benefit-to-risk ratio of oral anticoagulation (OAC) is disputed among patients with CKD stages G4 - G5 with AF, in particular among those receiving hemodialysis given their high risk for severe bleeding events. Novel strategies for stroke and systemic embolism prevention, particularly factor XI inhibitors and left atrial appendage occlusion (LAAO), have not yet fulfilled their initial promise as safe and effective alternatives.

Authors

Institutions

Publication Details

Journal
Nephrology Dialysis Transplantation
Published
2026-11-13
DOI
https://doi.org/10.1093/ndt/gfag263
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Atrial fibrillation in chronic kidney disease - treatment standard

Gunnar Henrik Heine, Wolfgang C. Winkelmayer­, An S. De Vriese, Marie Evans et al.
1 links
Nephrology Dialysis Transplantation
Atrial Fibrillation Management and Outcomes
article

Atrial fibrillation in chronic kidney disease - treatment standard

Gunnar Henrik Heine, Wolfgang C. Winkelmayer­, An S. De Vriese, Marie Evans, Ingo Eitel, Lukas Urbanek, Caroline Schneppe
article en

Abstract

The prevalence of atrial fibrillation (AF) is high among patients with chronic kidney disease (CKD). While patients with CKD Stages G1 - G3b may be treated similarly to patients without CKD, little evidence guides therapeutic strategies for CKD G4 - G5 patients. Dosing of most drugs used for rate and rhythm control requires adjustment to kidney function. Recurrence rates after cardioversion and ablation for rhythm control are higher in patients with advanced CKD than those without it. Regarding the prevention of stroke and systemic embolism, the benefit-to-risk ratio of oral anticoagulation (OAC) is disputed among patients with CKD stages G4 - G5 with AF, in particular among those receiving hemodialysis given their high risk for severe bleeding events. Novel strategies for stroke and systemic embolism prevention, particularly factor XI inhibitors and left atrial appendage occlusion (LAAO), have not yet fulfilled their initial promise as safe and effective alternatives.

Nephrology Dialysis Transplantation
Karolinska University Hospital (SE), Baylor College of Medicine (US), Karolinska Institutet (SE), Ghent University (BE), Cardiovascular Center Bethanien (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), AZ Sint-Jan (BE), KfH Kuratorium für Dialyse und Nierentransplantation (DE), Agaplesion Markus Hospital (DE), Saarland University (DE), University of Lübeck (DE)
Good health and well-being
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon